Not all biopsies are created equal. When it comes to planning radiation treatment, real-time MRI guidance makes all the difference. Learn how this advanced approach helps doctors target cancer more precisely and reduce the risk of prostate cancer returning. keep reading

Could a simple urine test change how prostate cancer is diagnosed? Research on urine spermine suggests it may help identify men at higher risk while sparing others from unnecessary biopsies. Combined with MRI, it offers a safer path to early detection. keep reading

“I wish I hadn’t chosen that treatment.” For many men with localized prostate cancer, decision regret is a painful reality. Studies show that clear communication, decision aids, and shared decision-making can help patients feel more confident and supported in their choices. keep reading

Is great care only about medical results? A large study suggests not. Patients consistently rated doctors higher when they felt listened to, understood, and respected, while poor communication and long wait times fueled dissatisfaction. keep reading

The “Prostate 8” program highlights eight lifestyle habits—from eating cruciferous vegetables and cooked tomatoes to avoiding whole milk—that research suggests may help men with prostate cancer improve outcomes. Together, these choices may reduce risks and restore a sense of control. keep reading

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

A European study of nearly 600 men found that negative prostate MRI results accurately predicted no cancer in 96% of cases. Over three years, most men safely avoided biopsy while being monitored, suggesting pre-biopsy MRI can reduce unnecessary procedures without added risk. keep reading

Prostate cancer trials often prioritize long-term survival data, but some experts say this narrow focus slows innovation and overlooks the patient experience. A growing call for change highlights the need for shorter, patient-centered studies that measure progress while protecting quality of life. keep reading

For decades, standard TRUS biopsies relied on 12+ random needles—missing aggressive cancers up to 46% of the time and increasing risks of infection. Today, real-time MRI-guided biopsies use just 2–4 precisely targeted needles, giving doctors clearer answers with fewer side effects. Discover why MRI-guided precision is changing prostate cancer diagnosis. keep reading

Gleason 3+3 prostate cancer is often considered low-risk—so low that some experts say it shouldn’t even be called cancer at all. But could a new label change how patients view their diagnosis and choices? The answer may reshape the future of prostate cancer care. keep reading